 Further insight in factors contributing to the initiation of NASH in patients with simple steatosis and early diagnosis are essential for identifying future therapeutic options and to limit the risk of complicated NASH i.e. fibrosis, and cirrhosis with portal hypertension HCC, liver-related mortality and extrahepatic morbidity. 